Asahi Kasei Group company Zoll Medical said it inked an exclusive strategic multi-year deal with advanced manufacturing company Myant to develop technologies for future versions of Zoll’s LifeVest wearable defibrillator.
The company’s LifeVest is designed to be worn by patients at risk of sudden cardiac death to monitor the heart continuously for abnormal heart arrhythmias and responds automatically, Zoll said. The system consists of an electrode belt and chest garment and a monitor worn around the waist or with a shoulder strap.
“This collaboration with Myant aligns with Zoll’s longstanding commitment to research and development with the goal of improving patient outcomes. We are excited to combine efforts with Myant and leverage their strong R&D capabilities, advanced manufacturing, and broad research capabilities from its Centers for Excellence in Canada and the US,” Zoll LifeVest prez Jason Whiting said in a press release.
“We are very proud of this exclusive agreement between Myant and Zoll because it represents a collaboration between two companies taking a multidisciplinary approach to advance technologies for future generations of wearable defibrillators. We are blending the benefits of advancements in materials science, state-of-the art machines, yarn with nanotechnology, and advanced manufacturing. It is an honor to work with Zoll, an extremely respected company and provider of FDA-approved, lifesaving medical devices,” Myant founder & CEO Tony Chahine said in a prepared statement.